Treatments for Diffuse Large B-cell Lymphoma in Elderly Patients
the Cancer Therapy Advisor take:
Patients older than 80 are less likely to receive the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as treatment for diffuse large B-cell lymphoma (DLBCL), according to an article published online in Cancer.
Data was provided from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Characterization was complete according to presentation, treatment, and survival patterns in patients diagnosed with DLBCL between 2002 and 2009.
Of the 4,635 patients included, 1,156 (25%) were older than 80. Instead of receiving R-CHOP, the patients over 80 years were more likely to be observed or receive the combination of rituximab, cyclophosphamide, vincristine, and prednisone (P<0.0001 for both).
Through multivariable Cox proportional hazards models, the R-CHOP therapy regimen was determined to be the only regimen associated with improved overall survival (hazard ratio, 0.45; 95% confidence interval: 0.33-0.62) and lymphoma-related survival (hazard ratio, 0.58; 95% confidence interval: 0.38-0.88).
The study suggests that R-CHOP be considered as a regimen for patients older than 80 years and further studies be conducted on the correlation of treatment of DLBCL and the quality of life of these patients.
Elderly patients less likely to receive combination R-CHOP for lymphoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma